Adaptive Biotechnologies (ADPT) Stock Price, News & Analysis

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adaptive Biotechnologies in the last twelve months. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ADPT shares.
View ADPT analyst ratings or view top-rated stocks.

6 brokerages have issued 12 month price targets for Adaptive Biotechnologies' stock. Their ADPT share price targets range from $5.00 to $10.00. On average, they predict the company's share price to reach $6.80 in the next year. This suggests a possible upside of 133.7% from the stock's current price.
View analysts price targets for ADPT or view top-rated stocks among Wall Street analysts.

Adaptive Biotechnologies' stock was trading at $4.90 on January 1st, 2024. Since then, ADPT shares have decreased by 40.6% and is now trading at $2.91.
View the best growth stocks for 2024 here.

Adaptive Biotechnologies saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 9,100,000 shares, an increase of 7.6% from the March 15th total of 8,460,000 shares. Based on an average daily volume of 1,490,000 shares, the days-to-cover ratio is presently 6.1 days. Approximately 6.6% of the shares of the company are short sold.
View Adaptive Biotechnologies' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our ADPT earnings forecast.

Adaptive Biotechnologies Co. (NASDAQ:ADPT) released its quarterly earnings results on Wednesday, February, 14th. The company reported ($0.30) EPS for the quarter, topping analysts' consensus estimates of ($0.32) by $0.02. The company had revenue of $45.78 million for the quarter, compared to analysts' expectations of $50.15 million. Adaptive Biotechnologies had a negative trailing twelve-month return on equity of 53.65% and a negative net margin of 132.29%.

ETFs with the largest weight of Adaptive Biotechnologies (NASDAQ:ADPT) stock in their portfolio include ARK Genomic Revolution ETF (ARKG) and Amplify Treatments, Testing and Advancements ETF (GERM).First Trust Nasdaq Lux Digital Health Solutions ETF (EKG).

Adaptive Biotechnologies updated its first quarter 2024 earnings guidance on Tuesday, April, 2nd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $41.0 million-$43.0 million, compared to the consensus revenue estimate of $38.2 million.

51 employees have rated Adaptive Biotechnologies Chief Executive Officer Chad Robins on Glassdoor.com. Chad Robins has an approval rating of 92% among the company's employees. This puts Chad Robins in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Adaptive Biotechnologies investors own include NVIDIA (NVDA), Alibaba Group (BABA), QUALCOMM (QCOM), Johnson & Johnson (JNJ), Advanced Micro Devices (AMD), CrowdStrike (CRWD), Home Depot (HD), Inovio Pharmaceuticals (INO), PayPal (PYPL) and Tesla (TSLA).

Adaptive Biotechnologies (ADPT) raised $200 million in an IPO on Thursday, June 27th 2019. The company issued 12,500,000 shares at $15.00-$17.00 per share. Goldman Sachs, J.P. Morgan and BofA Merrill Lynch served as the underwriters for the IPO and Cowen, Guggenheim Securities, William Blair and BTIG were co-managers.

Shares of ADPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.